文献速递免疫规划卫生政策与健康促进

开发低成本稳定液体人轮状病毒疫苗的制造工艺

Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine.
PubMed 文献 · Vaccine · 2021-03-18

RV3-BB候选疫苗在印尼婴儿中采用出生剂量策略对严重轮状病毒胃肠炎12月龄效力达94%。研究设定三剂次目标完全成本≤3.50美元,利用Vero细胞工厂高滴度工艺、开发2-8℃稳定两年液体剂型,临床剂量≤6.3 log10 FFU时达标,6.5 log10 FFU时成本远低于当前平均市场价2.44美元/剂。

要点

  • RV3-BB疫苗出生剂量策略在印尼婴儿中12月龄对严重轮状病毒胃肠炎效力达94%。
  • 三剂次目标完全成本≤3.50美元,临床剂量≤6.3 log10 FFU时达标。
  • 液体剂型2-8℃稳定两年,可能无需抗酸预处理,支持小体积给药。

核心结论

  • RV3-BB液体疫苗制造工艺可实现三剂次成本≤3.50美元目标,临床剂量≤6.3 log10 FFU时达标。
  • 临床剂量6.5 log10 FFU时最终工艺成本远低于当前平均市场价2.44美元/剂。
  • 工艺与剂型已转移至印尼BioFarma以支持未来RV3-BB疫苗生产。

研究设计与样本

  • 原文为制造工艺开发研究,未报告临床试验样本量或研究设计细节。
  • 基于预测市场需求设定三剂次目标完全成本≤3.50美元。
  • 利用成本建模开发Vero细胞工厂高滴度工艺,并开发液体剂型。

主要发现

  • RV3-BB疫苗出生剂量策略在印尼婴儿中12月龄对严重轮状病毒胃肠炎效力达94%。
  • 液体剂型可实现2-8℃储存两年。
  • 剂型可能免去接种前抗酸预处理,允许小体积给药并降低供应链成本。
  • 临床剂量≤6.3 log10 FFU时三剂次成本≤3.50美元目标达标。
  • 临床剂量6.5 log10 FFU时最终工艺成本远低于当前平均市场价2.44美元/剂。

关键数值与推荐

  • 目标完全成本≤3.50美元/三剂次。
  • 临床剂量≤6.3 log10 FFU时成本目标达标。
  • 临床剂量6.5 log10 FFU时成本远低于当前平均市场价2.44美元/剂。
  • 液体剂型2-8℃稳定两年。

临床怎么用

  • 该工艺支持低成本、稳定液体RV3-BB疫苗的生产与供应链简化。
  • 液体剂型可能无需抗酸预处理,便于口服接种。
  • 马拉维剂量范围研究正在进行,将确定最终临床剂量。

局限性

  • 原文未报告工艺开发的具体实验数据或统计细节。
  • 最终临床剂量尚未确定,马拉维剂量范围研究正在进行。
  • 成本基于模型预测,实际生产成本可能受多种因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite solid evidence of the success of rotavirus vaccines in saving children from fatal gastroenteritis, more than 82 million infants worldwide still lack access to a rotavirus vaccine. The main barriers to global rotavirus vaccine coverage include cost, manufacturing capacity and suboptimal efficacy in low- and lower-middle income countries. One vaccine candidate with the potential to address the latter is based on the novel, naturally attenuated RV3 strain of rotavirus, RV3-BB vaccine administered in a birth dose strategy had a vaccine efficacy against severe rotavirus gastroenteritis of 94% at 12 months of age in infants in Indonesia. To further develop this vaccine candidate, a well-documented and low-cost manufacturing process is required. A target fully loaded cost of goods (COGs) of ≤$3.50 per course of three doses was set based on predicted market requirements. COGs modelling was leveraged to develop a process using Vero cells in cell factories reaching high titers, reducing or replacing expensive reagents and shortening process time to maximise output. Stable candidate liquid formulations were developed allowing two-year storage at 2-8 °C. In addition, the formulation potentially renders needless the pretreatment of vaccinees with antacid to ensure adequate gastric acid neutralization for routine oral vaccination. As a result, the formulation allows small volume dosing and reduction of supply chain costs. A dose ranging study is currently underway in Malawi that will inform the final clinical dose required. At a clinical dose of ≤6.3 log10 FFU, the COGs target of ≤$3.50 per three dose course was met. At a clinical dose of 6.5 log10 FFU, the final manufacturing process resulted in a COGs that is substantially lower than the current average market price, 2.44 USD per dose. The manufacturing and formulation processes were transferred to BioFarma in Indonesia to enable future RV3-BB vaccine production.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hamidi A, Hoeksema F, Velthof P, et al. Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine. Vaccine. 2021. PMID: 33744044. doi:10.1016/j.vaccine.2021.03.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。